Literature DB >> 16421733

Validation of the German prostate-specific module.

Beate Bestmann1, Volker Rohde, Jens-Ulrich Siebmann, Razvan Galalae, Wolfgang Weidner, Thomas Küchler.   

Abstract

Theoretically, all patients newly diagnosed with prostate cancer are faced with a choice of treatment options: radical prostatectomy or radio therapy. Although these different treatments may have no differences in terms of survival, they may have very different consequences on the subsequent quality of life (QoL). Prerequisite to analyze QoL is a reliable and valid instrument to assess these differences not only in terms of general QoL (EORTC QLQ-C30) but prostate specific symptoms with a prostate specific module as well. Therefore, the aim of this study was a psychometric evaluation (validation) of the prostate-specific module (PSM). Five historical cohort studies were put together for an empirical meta-analysis. The main objective was to analyze the module's psychometric properties. The total sample consisted of 1,185 patients, of whom 950 completed the QoL questionnaires (EORTC QLQ-C30 and a prostate specific module developed by Kuechler et al.). First step of analysis was a principal component analysis that revealed the following scales: urinary problems, incontinence, erectile dysfunction, sexual problems, problems with partner, pain, heat, nutrition, and psychic strain. The module showed good reliability and concurrent validity and very good construct validity, since the module is able to discriminate between different treatment regimes, tumor stages and age. The German PSM is a reliable, valid and applicable tool for QoL in patients with prostate cancer.

Entities:  

Mesh:

Year:  2006        PMID: 16421733     DOI: 10.1007/s00345-005-0023-5

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  5 in total

1.  PSA thresholds for prostate cancer detection.

Authors:  M E Parker
Journal:  JAMA       Date:  1997-09-03       Impact factor: 56.272

2.  Will increases in chemotherapy dose intensity improve outcome of patients with common malignancies?

Authors:  I Tannock
Journal:  Am J Med       Date:  1995-12-29       Impact factor: 4.965

3.  Quality of life after treatment for localized prostate cancer: differences based on treatment modality.

Authors:  J W Davis; D A Kuban; D F Lynch; P F Schellhammer
Journal:  J Urol       Date:  2001-09       Impact factor: 7.450

4.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

5.  The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure.

Authors:  M S Litwin; R D Hays; A Fink; P A Ganz; B Leake; R H Brook
Journal:  Med Care       Date:  1998-07       Impact factor: 2.983

  5 in total
  2 in total

1.  [Quality of life after prostate cancer in members of support groups: first results of the HAROW retro study].

Authors:  B Bestmann; T Kollakowski; L Weissbach
Journal:  Urologe A       Date:  2011-03       Impact factor: 0.639

2.  The ProCaSP study: quality of life outcomes of prostate cancer patients after radiotherapy or radical prostatectomy in a cohort study.

Authors:  Nora Eisemann; Sandra Nolte; Maike Schnoor; Alexander Katalinic; Volker Rohde; Annika Waldmann
Journal:  BMC Urol       Date:  2015-04-10       Impact factor: 2.264

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.